Similar articles

• Anti-interleukin-5 therapy and severe asthma.

  Zarogiannis S, Gourgoulianis KI, Kostikas K. Zarogiannis S, et al. N Engl J Med. 2009 Jun 11;360(24):2576; author reply 2577. doi: 10.1056/NEJMc090685. N Engl J Med. 2009. PMID: 19516040 No abstract available.
• Anti-interleukin-5 therapy and severe asthma.

  Gleich GJ. Gleich GJ. N Engl J Med. 2009 Jun 11;360(24):2577; author reply 2578. N Engl J Med. 2009. PMID: 19522047 No abstract available.
• Eosinophils in asthma--closing the loop or opening the door?

  Wenzel SE. Wenzel SE. N Engl J Med. 2009 Mar 5;360(10):1026-8. doi: 10.1056/NEJMe0900334. N Engl J Med. 2009. PMID: 19264692 No abstract available.
• [CME: Mepolizumab, an Additional Therapeutic Agent for Severe Asthma].

  Platzer S, Fehr T, Latshang T. Platzer S, et al. Praxis (Bern 1994). 2018;107(21):1129-1135. doi: 10.1024/1661-8157/a003076. Praxis (Bern 1994). 2018. PMID: 30326819 Review. German.
• Eosinophils and interleukin-5: the debate continues.

  Kay AB, Menzies-Gow A. Kay AB, et al. Am J Respir Crit Care Med. 2003 Jun 15;167(12):1586-7. doi: 10.1164/rccm.2304001. Am J Respir Crit Care Med. 2003. PMID: 12796050 Review. No abstract available.